Fig. 2: Efficacy endpoints. | Nature Communications

Fig. 2: Efficacy endpoints.

From: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Fig. 2: Efficacy endpoints.The alternative text for this image may have been generated using AI.

a Primary endpoint result: clinical benefit rate (CBR), including patients in stable disease (SD), partial response (PR) and complete response (CR) at week 24 per treatment arm. Statistical significance was tested with a one-sided Fisher’s exact test. b Distribution of responses as defined by RECIST 1.1 among patients evaluable at week 24. c CBR according to PD-L1 status. Two-sided Fisher’s exact test. d CBR according to CD73 status. Two-sided Fisher’s exact test. e Kaplan–Meier estimates of progression-free survival (PFS) by RECIST v1.1 according to treatment arm. One-sided log-rank test. f Kaplan–Meier estimates of overall survival (OS) according to treatment arm. One-sided log-rank test. Source data are provided as a Source data file.

Back to article page